Consensus Alto Neuroscience, Inc.

Equities

Market Closed - Nyse Other stock markets 04:00:02 2024-05-20 pm EDT			5-day change	1st Jan Change
12.4 ^USD	-0.56%		-11.99%	0.00%

May. 14	Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia	CI

320c48d.hg9dRJnI6gUGBEBtfuQWBfyNpYtBaLyBOE9PwvsK-wg.zD8HD6ifmEZAR3ICGrcnUM7o37gLDenHSw0Zh7RFz3_jRisQ9rKtTUpgJw~72a6f21a9eec6f850e74e318f9e9bdb5

Stifel Initiates Alto Neuroscience With Buy Rating, Price Target is $32	Feb. 27	MT
Baird Initiates Alto Neuroscience With Outperform Rating, Price Target is $32	Feb. 27	MT
Jefferies Initiates Alto Neuroscience With Buy Rating, Price Target is $33	Feb. 27	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.47 USD

Average target price

33.69 USD

Spread / Average Target

+170.17%

High Price Target

37.76 USD

Spread / Highest target

+202.81%

Low Price Target

32 USD

Spread / Lowest Target

+156.62%